We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ingenuity Licenses Pathways Analysis Software to Avalon
News

Ingenuity Licenses Pathways Analysis Software to Avalon

Ingenuity Licenses Pathways Analysis Software to Avalon
News

Ingenuity Licenses Pathways Analysis Software to Avalon

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ingenuity Licenses Pathways Analysis Software to Avalon"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ingenuity Systems and Avalon Pharmaceuticals Inc. have announced that they have entered into an agreement whereby Avalon will license Ingenuity Pathways Analysis 3.0, enhancing Avalon's drug and target discovery process.

Avalon has a focused program to harness the power of gene disruption signatures for the isolation of drugs against previously "intractable" targets.

The Ingenuity Pathways Analysis 3.0 application is being applied to the AvalonRx® platform in several selected therapeutic areas to identify biomarkers, targets, and compounds.

Ingenuity Pathways Analysis 3.0 is designed to enable researchers to model, analyze and understand the complex biological systems at the core of life science research.

Ingenuity claims that, with Ingenuity Pathways Analysis, scientists can integrate their own biological discoveries into Ingenuity networks, providing effective computation and functional analysis.

Advertisement